title: Novel emerging treatments for hepatitis C infection: a fast-moving pipeline.
abstract: Advances in the treatment of chronic hepatitis C has been one of the pinnacles of medical science in the last 25 years. The age of direct-acting antivirals (DAAs) has led to cure rates >95% with shorter duration and low toxicity regimens, thus changing the landscape of the era of pegylated interferon and ribavirin (RBV). However, there remain some challenges with these therapies as there are multiple regimens available with a fair amount of sophistication required to administer them. Treatment continues to require knowledge of prior treatment status, viral genotype and fibrosis assessment, thus affording an opportunity for improvement in future regimens. This update reviews some upcoming therapies for the treatment of chronic hepatitis C.
authors.affiliation: Fellow, Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, USA.
authors.forename: Ara A
authors.initials: AA
authors.lastname: Kardashian
authors.affiliation: Director of Clinical Research, Scripps Translational Science Institute, Scripps Clinic, 10666 N Torrey Pines Rd, La Jolla, CA 92037, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Pockros
keywords: direct-acting antivirals; emerging treatments; hepatitis C